Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Operating Expenses Over TimeContracting
Percentile Rank87
3Y CAGR+1.4%
5Y CAGR+10.8%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+1.4%/yr
vs +10.2%/yr prior
5Y CAGR
+10.8%/yr
Recent deceleration
Acceleration
-8.8pp
Decelerating
Percentile
P87
Within normal range
vs 5Y Ago
1.7x
Solid growth
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$36.61M-11.4%
2024$41.31M-20.6%
2023$52.00M+48.0%
2022$35.13M+37.3%
2021$25.58M+16.6%
2020$21.95M+1.4%
2019$21.65M-9.1%
2018$23.83M-11.5%
2017$26.91M+0.2%
2016$26.85M-